RhoB regulates uPAR signalling

Journal of Cell Science

Volumn 125, Issue 10, 2012, Pages 2369-2380

  Alfano, Daniela ^a,b,c   Ragno, Pia ^b   Stoppelli, M Patrizia ^c   Ridley, Anne J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SALERNO   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Cell migration; Rho GTPases; Signal transduction; uPA; uPAR

Indexed keywords

ACTIN; ACTIVATING TRANSCRIPTION FACTOR; AURORA A KINASE; COFILIN; INTEGRIN; PAXILLIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; UROKINASE; VITRONECTIN;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

CELL ADHESION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; INTEGRINS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RHOB GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 84864819464     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.091579     Document Type: Article

References (66)

1. Aguirre-Ghiso, J. A., Estrada, Y., Liu, D. and Ossowski, L. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63, 1684-1695.
2. Alfano, D., Franco, P., Vocca, I., Gambi, N., Pisa, V., Mancini, A., Caputi, M., Vincenza Carriero, M., Iaccarino, I. and Stoppelli, M. P. (2005). The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb. Haemost. 93, 205-211.
3. Alfano, D., Iaccarino, I. and Stoppelli, M. P. (2006). Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J. Biol. Chem. 281, 17758-17767.
4. Almasi, C. E., Brasso, K., Iversen, P., Pappot, H., Høyer-Hansen, G., Danø, K. and Christensen, I. J. (2011). Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 71, 899-907.
5. Bai, S. W., Herrera-Abreu, M. T., Rohn, J. L., Racine, V., Tajadura, V., Survavanshi, N., Bechtel, S., Wiemann, S., Baum, B. and Ridley, A. J. (2011). Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. BMC Biol. 9, 54.
6. Bamburg, J. R. (1999). Proteins of the ADF/cofilin family: essential regulators of actin dynamics. Annu. Rev. Cell Dev. Biol. 15, 185-230.
7. Blasi, F. and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943.
8. Blasi, F. and Sidenius, N. (2010). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 584, 1923-1930.
9. Calderwood, D. A. (2004). Integrin activation. J. Cell Sci. 117, 657-666.
10. Canguilhem, B., Pradines, A., Baudoin, C., Boby, C., Lajoie-Mazenc, I., Charveron, M. and Favre, G. (2005). RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J. Biol. Chem. 280, 43257-43263.
11. Caswell, P. T., Vadrevu, S. and Norman, J. C. (2009). Integrins: masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol. 10, 843-853.
12. Chandrasekar, N., Mohanam, S., Gujrati, M., Olivero, W. C., Dinh, D. H. and Rao, J. S. (2003). Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 22, 392-400.
13. Connolly, E. C., Van Doorslaer, K., Rogler, L. E. and Rogler, C. E. (2010). Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol. Cancer Res. 8, 691-700.
14. Bousquet, E., Mazières, J., Privat, M., Rizzati, V., Casanova, A., Ledoux, A., Mery, E., Couderc, B., Favre, G. and Pradines, A. (2009). Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1. Cancer Res. 69, 6092-6099.
15. Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M. and Rømer, J. (2005). Plasminogen activation and cancer. Thromb. Haemost. 93, 676-681.
16. Deakin, N. O. and Turner, C. E. (2008). Paxillin comes of age. J. Cell Sci. 121, 2435-2444.
17. Dedhar, S., Saulnier, R., Nagle, R. and Overall, C. M. (1993). Specific alterations in the expression of a3b1 and a6b4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin. Exp. Metastasis 11, 391-400.
18. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. and Loskutoff, D. J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
19. Franco, P., Vocca, I., Vincenza Carriero, M., Alfano, D., Cito, L., Longanesi-Cattani, I., Grieco, P., Ossowski, L. and Stoppelli, M. P. (2006). Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and avb5 integrin. J. Cell Sci. 119, 3424-3434.
20. Fritz, G., Kaina, B. and Aktories, K. (1995). The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem. 270, 25172-25177.
21. Harbeck, N., Kates, R. E., Look, M. P., Meijer-Van Gelder, M. E., Klijn, J. G., Krüger, A., Kiechle, M., Jänicke, F., Schmitt, M. and Foekens, J. A. (2002). Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n 5 3424). Cancer Res. 62, 4617-4622.
22. Heasman, S. J. and Ridley, A. J. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9, 690-701.
23. Huang, M. and Prendergast, G. C. (2006). RhoB in cancer suppression. Histol. Histopathol. 21, 213-218.
24. Huang, M., Duhadaway, J. B., Prendergast, G. C. and Laury-Kleintop, L. D. (2007). RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 27, 2597-2605.
25. Irigoyen, J. P., Muñoz-Cánoves, P., Montero, L., Koziczak, M. and Nagamine, Y. (1999). The plasminogen activator system: biology and regulation. Cell. Mol. Life Sci. 56, 104-132.
26. Jähner, D. and Hunter, T. (1991). The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol. Cell. Biol. 11, 3682-3690.
27. Jo, M., Thomas, K. S., Somlyo, A. V., Somlyo, A. P. and Gonias, S. L. (2002). Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J. Biol. Chem. 277, 12479-12485.
28. Kiian, I., Tkachuk, N., Haller, H. and Dumler, I. (2003). Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb. Haemost. 89, 904-914.
29. Kjoller, L. and Hall, A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-2257.
30. Lebowitz, P. F., Davide, J. P. and Prendergast, G. C. (1995). Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15, 6613-6622.
31. Liu, A. X., Rane, N., Liu, J. P. and Prendergast, G. C. (2001). RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol. Cell. Biol. 21, 6906-6912.
32. Llinas, P., Le Du, M. H., Gårdsvoll, H., Danø, K., Ploug, M., Gilquin, B., Stura, E. A. and Ménez, A. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663.
33. Madsen, C. D. and Sidenius, N. (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol. 87, 617-629.
34. Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O. and Sidenius, N. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 177, 927-939.
35. Margheri, F., Manetti, M., Serratì, S., Nosi, D., Pucci, M., Matucci-Cerinic, M., Kahaleh, B., Bazzichi, L., Fibbi, G., Ibba-Manneschi, L. et al. (2006). Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 54, 3926-3938.
36. Monferran, S., Skuli, N., Delmas, C., Favre, G., Bonnet, J., Cohen-Jonathan-Moyal, E. and Toulas, C. (2008). avb3 and avb5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int. J. Cancer 123, 357-364.
37. Montuori, N., Visconte, V., Rossi, G. and Ragno, P. (2005). Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93, 192-198.
38. Montuori, N., Bifulco, K., Vincenza Carriero, M., La Penna, C., Visconte, V., Alfano, D., Pesapane, A., Rossi, F. W., Salzano, S., Rossi, G. et al. (2011). The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell. Mol. Life Sci. 68, 2453-2467.
39. Muller, S. M., Okan, E. and Jones, P. (2000). Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. Biochem. Biophys. Res. Commun. 270, 892-898.
40. Oser, M. and Condeelis, J. (2009). The cofilin activity cycle in lamellipodia and invadopodia. J. Cell. Biochem. 108, 1252-1262.
41. Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M. and Rao, J. S. (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280, 36529-36540.
42. Rabbani, S. A., Ateeq, B., Arakelian, A., Valentino, M. L., Shaw, D. E., Dauffenbach, L. M., Kerfoot, C. A. and Mazar, A. P. (2010). An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 12, 778-788.
43. Ridley, A. J. (2006). Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16, 522-529.
44. Riento, K., Guasch, R. M., Garg, R., Jin, B. and Ridley, A. J. (2003). RhoE binds to ROCK I and inhibits downstream signaling. Mol. Cell. Biol. 23, 4219-4229.
45. Rodriguez, P. L., Sahay, S., Olabisi, O. O. and Whitehead, I. P. (2007). ROCK I-mediated activation of NF-kappaB by RhoB. Cell. Signal. 19, 2361-2369.
46. Sandilands, E., Cans, C., Fincham, V. J., Brunton, V. G., Mellor, H., Prendergast, G. C., Norman, J. C., Superti-Furga, G. and Frame, M. C. (2004). RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev. Cell 7, 855-869.
47. Schaller, M. D. and Parsons, J. T. (1995). pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Mol. Cell. Biol. 15, 2635-2645.
48. Sehgal, I., Foster, T. P. and Francis, J. (2006). Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis. Cancer Cell Int. 6, 21.
49. Sheng, S. (2001). The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev. 20, 287-296.
50. Smith, H. W. and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23-36.
51. Smith, H. W., Marra, P. and Marshall, C. J. (2008). uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J. Cell Biol. 182, 777-790.
52. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F. and Assoian, R. K. (1985). Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA 82, 4939-4943.
53. Sturge, J., Hamelin, J. and Jones, G. E. (2002). N-WASP activation by a b1-integrindependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator. J. Cell Sci. 115, 699-711.
54. Tang, H., Kerins, D. M., Hao, Q., Inagami, T. and Vaughan, D. E. (1998). The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273, 18268-18272.
55. Vasilaki, E., Papadimitriou, E., Tajadura, V., Ridley, A. J., Stournaras, C. and Kardassis, D. (2010). Transcriptional regulation of the small GTPase RhoB gene by TGFbeta-induced signaling pathways. FASEB J. 24, 891-905.
56. Vassalli, J. D., Baccino, D. and Belin, D. (1985). A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100, 86-92.
57. Vega, F. M. and Ridley, A. J. (2008). Rho GTPases in cancer cell biology. FEBS Lett. 582, 2093-2101.
58. Vega, F., Fruhwirth, G., Ng, T. and Ridley, A. J. (2011). RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J. Cell Biol. 193, 655-665.
59. Vincenza Carriero, M. and Stoppelli, M. P. (2011). The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr. Pharm. Des. 17, 1944-1961.
60. Vincenza Carriero, M., Franco, P., Vocca, I., Alfano, D., Longanesi-Cattani, I., Bifulco, K., Mancini, A., Caputi, M. and Stoppelli, M. P. (2009). Structure, function and antagonists of urokinase-type plasminogen activator. Front. Biosci. 14, 3782-3794.
61. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V. and Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
62. Wheeler, A. P. and Ridley, A. J. (2004). Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301, 43-49.
63. Wheeler, A. P. and Ridley, A. J. (2007). RhoB affects macrophage adhesion, integrin expression and migration. Exp. Cell Res. 313, 3505-3516.
64. Wherlock, M., Gampel, A., Futter, C. and Mellor, H. (2004). Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell Sci. 117, 3221-3231.
65. Yoneda, M., Hirokawa, Y. S., Ohashi, A., Uchida, K., Kami, D., Watanabe, M., Yokoi, T., Shiraishi, T. and Wakusawa, S. (2010). RhoB enhances migration and MMP1 expression of prostate cancer DU145. Exp. Mol. Pathol. 88, 90-95.
66. Zhou, J., Zhu, Y., Zhang, G., Liu, N., Sun, L., Liu, M., Qiu, M., Luo, D., Tang, Q., Liao, Z. et al. (2011). A distinct role of RhoB in gastric cancer suppression. Int. J. Cancer 128, 1057-1068.